Loading
The pathologist is the first person to know a cancer is rare or has a targetable marker. A rule in the lab system could notify a trial team at that moment, before treatment decisions close the window.
Laboratory information systems flag defined diagnoses (rare histologies, MSI-high, NTRK fusion, specific paediatric-type tumours in adults) and send a structured notification to a regional trial coordination office and the treating clinician, with matched trials attached. Consent-to-contact rules govern direct patient contact. Precedents exist in stroke and sepsis alerting; oncology pathology alerting has been used for HER2 and MSI testing completeness.
Shares Trials enrol too few, too slowly, Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Digital pathology & AI, Histopathology & immunohistochemistry.
Shares Digital pathology & AI, Histopathology & immunohistochemistry.
Shares Digital pathology & AI, Histopathology & immunohistochemistry, Rare and paediatric cancers without markets, Neuroendocrine tumours.
Shares Digital pathology & AI, Histopathology & immunohistochemistry.
Shares Trials enrol too few, too slowly, Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).